Fungal infections in patients with chronic granulomatous disease (CGD) are a poor prognostic factor. We describe the first case of CGD with femoral osteomyelitis due to Cladophialophora arxii, which is a member of the dematiaceous group. The causative fungus was identified on the basis of its morphological characteristics, growth temperature profile, and nucleotide sequence on the internal transcribed space region of the ribosomal gene. The patient was successfully treated with surgical debridement, subsequent administration of itraconazolem and interferon-c.
Introduction
Chronic granulomatous disease (CGD) is a rare, inherited primary immunodeficiency disease that results from defects in phagocytic cells associated with the low activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [1] . CGD patients are susceptible to infections, especially those caused by catalase-producing bacteria, such as Staphylococcus, Burkholderia, Serratia, and Nocardia, and fungi, such as Aspergillus species [2] . Dematiaceous fungi, such as Cladophialophora arxii, which are characterized by black melanin pigment, are isolated less frequently in CGD patients.
We report a patient with CGD who developed femoral osteomyelitis due to C. arxii. The patient underwent a successful treatment with surgical debridement and administration of itraconazole and IFN-c.
Case Report
The patient was 20-year-old man with X-linked CGD. The diagnosis of CGD had been established at the age of 6 years, at which time he presented with cervical lymphadenitis, BCG lymphadenitis, a perirectal abscess, and recurrent pneumonia; the neutrophil nitroblue tetrazolium reduction was abnormal. He was treated with prophylactic therapy consisting of trimethoprim-sulfamethoxazole and oral itraconazole capsules (100 mg once daily) and developed no other serious infections until 20 years of age. However, pulmonary granulomas had been formed following an episode of pneumonia at the age of 7 years, and these had remained, gradually growing during the following 13 years. He occasionally had hemoptysis.
The patient presented with an approximately 2-week history of pain in the posterior, distal left thigh without fever. On admission, he complained of knee pain that made walking difficult. Laboratory findings included a leukocyte count of 3,950/ll, with 76% neutrophils; C-reactive protein (CRP) level, 13.8 mg/l; erythrocyte sedimentation rate, 23 mm/h; ß-D-glucan (ß-glucan Wako), 14.78 pg/ml (normal range < 11 pg/ml). Before this episode, ß-D-glucan levels had been negative. Aspergillus DNA and Aspergillus galactomannan antigen in the blood were undetectable. Blood cultures showed no growth.
A roentgenogram of the painful area showed no abnormalities, but magnetic resonance imaging suggested osteomyelitis ( Figure 1) . A computerized tomography scan of the chest revealed a 2.5-cm nodule in the right hilar region, which partly compressed the bronchial tube, a 1.5-cm nodule in the left upper lobe, and numerous small nodules scattered throughout both lungs. Enlarged lymph nodes with calcification in the superior mediastinum, left axilla, and hepatic portal region were present. Empiric therapy with an oral itraconazole solution (200 mg once daily) and iv injection of micafungin (250 mg per day) was started because the clinical and laboratory findings suggested fungal osteomyelitis. The plasma itraconazole concentration measured with by high performance liquid chromatography, which was 626.0 ng/ml on admission, had elevated to 2,573.4 ng/ml by the third day of hospitalization. The following day, extensive surgical debridement of the lesion was performed. Pus discharge from the bone marrow was observed following the drilling of a hole in the cortex. Fungal elements were seen in the necrotic bone tissue. The culture of this specimen on Sabouraud dextrose agar (Becton Dickinson Microbiology Systems, Tokyo, Japan) yielded several colonies with no bacteria present after 14 days. These colonies were dark gray and consisted of septate hyphae with smooth oval conidia. At this point, the fungus was tentatively identified as Cladosporium species. The patient showed clinical and laboratory signs of improvement on the 14th day of hospitalization. Therapy with itraconazole and micafungin was continued, but the level of inflammatory markers rose gradually (CRP from 2.7 to 10.5 mg/l), and the plasma itraconazole concentration decreased to 1,596.6 ng/ml. IFN-c therapy (25 lg/m 2 two times per week) was added to the therapeutic regimen on the 24th day, and the route of itraconazole administration was changed on the 25th day, with new treatment consisting of itraconazole iv for 12 days (200 mg once daily) followed by oral capsules (200 mg twice daily). These changes in the patient's therapeutic regimen increased the plasma itraconazole concentration to over 5,000 ng/ml and decreased the CRP level to within the normal range. Micafungin was discontinued on the day of discharge (40th day after admission), while treatment with itraconazole and IFN-c was continued. The plasma itraconazole levels stayed within the range of 7,000-8,000 ng/ml. Five months after surgery, the patient had no signs of recurrent disease, but there was little change in the pulmonary granulomas. There were no side effects as a result of the drugs given.
At the time of discharge, we had identified the isolated fungus as C. arxii. The MICs of itraconazole, micafungin, amphotericin B, voriconazole, flucytosine, miconazole, and fluconazole against the present isolate were 0.03 mg/l, 0.125 mg/l, 0.25 mg/l, 0.5 mg/l, 1 mg/l, 1 mg/l, and 64 mg/l, respectively. The MICs were established after 5 days of incubation and determined by the ASTY (Kyokuto Pharmaceutical Industrial Co, Tokyo, Japan) colorimetric microdilution testing system [3] . Neutrophil superoxide production on flow cytometric analysis with dihydrorhodamine 123 was 0.3% of that of control neutrophils before IFN-c therapy. Despite continuous IFN-c therapy, periodic clinical examinations revealed no increase in superoxide production by the patient's neutrophils.
Mycological Examination
Colonies of the causative fungus grew slowly, attaining a diameter of approximately 40 mm and 36 mm on synthetic defined agar (SDA; Difco, Detroit, MI) and potato dextrose agar (PDA; Difco) plates, respectively, at 25°C after 35 days. They were dark grayish with aerial hyphae and blackish brown with creeping hyphae at the margin on SDA (Figure 2a ) and blackish brown, felty with radial furrows on PDA. The hyphae were septate and olivaceous brown and produced laterally and terminally acropetal conidial chains that branched profusely. The conidia were pale brown to brown, smooth-and somewhat thickwalled, lemon-to spindle-shaped, and 5-13 · 3-4 lm with hila ( Figure 2b ). The isolate had restricted growth at 35°C, barely grew at 37°C and did not grow at all at 40°C.
DNA was extracted by the benzyl chloride method from isolates cultured on PDA at 25°C for 7 days, and the internal transcribed spacer (ITS) region including 5.8 S of ribosomal RNA gene (ITS1-5.8S-ITS2 rRNA) was amplified with the primer pair ITS5 (5¢-GGA AGTAAAAGTCGTAACAAGG-3¢) and ITS4 (5¢-TCCTCCGCTTATTGATATG-3¢). The PCR products were labeled by ITS1 (5¢-TCCGTAGGTGAACCTGC GG-3¢) and ITS4. A total of 528 bases were determined, and these showed a 98% homology against the ITS region in C. arxii IFM 52022 (Accession No. AB109181), derived from the type strain CBS 306.94.
Based on these results, the causative fungus was identified as C. arxii, and the sequence was registered at DNA Data Bank of Japan (DDBJ), National Institute of Genetics as Accession No. AB458597.
Discussion
CGD patients have frequent life-threatening bacterial and fungal infections because superoxide production is decreased in their phagocytes [1] . Such patients usually suffer from infections of the skin, lymph nodes, lungs, liver, and gastrointestinal tract, with the lungs being the most common sites of infections. The overall incidence of fungal infections has been reported to be 20% among patients with CGD [4] . Aspergillus species are the most common cause of fungal infections, but there have been a few reports of other infections caused by other fungal species. Although pulmonary infections due to Aspergillus species are common, fungal osteomyelitis due to Aspergillus species is uncommon. In particular, long bone osteomyelitis due to non-Aspergillus fungi has been re- 
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ported only rarely [5] . Osteomyelitis may be a part of a systemic infection, or it may be the only localized focus of infection. In the case reported here, the patient had pulmonary granulomas that partly compressed the bronchial tube as well as hemoptysis on occasion. We hypothesized that the causative fungus disseminated into the bone lesion through the bloodstream from the lung lesion, which may have been caused by air-bone infection. Therefore, we expected that itraconazole therapy would at least diminish the size of the pulmonary granulomas that had formed during the preceding 13 years. However, this therapy did not result in such a favorable response.
Cladophialophora arxii is a relatively new member of the dematiaceous group of mycelial fungal pathogens, being reported as a new species of the genus Cladophialophora in 1995 [6] . The identification of this species is often difficult because of its rarity and morphological similarity to some other Cladophialophora species. The morphology of the conidial system of C. arxii is very similar to that of Cladophialophora devriesii, and C. devriesii also grows at 37°C but not at 40°C. However, the conidial chains of the fungus isolated from our patient are slightly longer than those of C. devriesii, and the identity of the ITS region of the rRNA gene shows only an 89-90% similarity with C. devriesii. Even though the growth temperature profile is similar to that of C. devriesii, the conidial morphology and DNA identity strongly suggest that the present isolate is C. arxii and not C. devriesii. Generally speaking, maximum growth temperatures (MaxGT) of the dematiaceous fungi are not strict; for example, the MaxGT of a principal dematiaceous fungal pathogen, Fonsecaea prodrosoi, ranges from 38°C to 42°C. The MaxGT of C. arxii for most isolates is probably in the range of 37-40°C. Thus, the fungus isolated from our patient can be clearly differentiated by conidial morphology, MaxGT, and identity (88%) on the ITS region from C. bantiana, which is characterized by long ellipsoidal or nearly cylindrical conidia consisting of very long, poorly branched chains and good growth at 37°C (MaxGT 40-45°C). The identification of such a rare and slow-growing fungus is time-consuming and requires expert knowledge of the morphology and physiology of the fungus. Consequently, an analysis of the ITS region on the rRNA gene facilitates an early diagnosis and species differentiation. However, we have to be careful when accessing the names of fungi with sequence identities using the nucleotide databases of NCBI BLAST (National Center for Biotechnology Information, Basic Local Alignment Search Tool; National Institutes of Health, Bethesda, MDA). The fungal listings in these databases sometimes mention several or more names of fungi that actually belong to different genera or species. In order to obtain the correct name for a fungus, especially a filamentous one, morphological, physiological, and biochemical studies should be carried out simultaneously.
Dematiaceous fungi have been recognized as etiologic agents of phaeohyphomycosis, chromoblastomycosis, and eumycotic mycetoma. Although disseminated infection caused by dematiaceous fungi is uncommon, it has been increasingly recognized as a cause of serious disease, especially in immunodeficient patients. Brain abscesses due to C. bantiana are the commonest form of systemic phaeohyphomycosis [7] . Other localized deep forms of infections, such as arthritis [8] , endocarditis [9] , and osteomyelitis [10] , have been rarely reported. Cladophialophora devriesii is a very rare pathogen and reported to have caused fatal dissemination [11, 12] . Our patient had femoral osteomyelitis due to C. arxii. To the best of our knowledge, this is the first documented case of osteomyelitis caused by a dematiaceous fungus in CGD patients. In addition, C. arxii is an extremely rare species, and this is only the second reported case of C. arxii infection in humans.
Although guidelines for treatment of fungal osteomyelitis due to non-Aspergillus fungi are not well established, surgery generally plays an important role in the management of CGD patients [13] . In cases of Aspergillus osteomyelitis, surgical debridement appears to be very important for a successful treatment, and extensive debridement is more effective than limited intralesional debridement [14] . Invasive fungal infections are a major cause of morbidity and mortality in CGD patients, and other rare and emerging fungi can cause significant diseases. The treatment of fungal infections involves the prolonged use of systemic antifungal agents and, in some cases, the causative fungi may be refractory to antifungal treatment. Therefore, extensive surgical debridement is also likely to be necessary in cases of non-Aspergillus fungi osteomyelitis.
Itraconazole has a broad spectrum of activity against many infections caused by pathogenic fungi, and it is well tolerated and safe [15] . Prophylactic itraconazole is effective in preventing fungal infection in CGD patients [16] . However, low plasma itraconazole concentrations can cause a failure of prophylaxis or treatment. The absorption of itraconazole when given as a capsule formulation is highly variable [17] ; for example, adequate absorption requires an acid gastric environment and the presence of food.
In the case reported here, we selected itraconazole regardless of the patient suffering from fungal infection during itraconazole prophylaxis. This choice of treatment was based on the evidence that the CRP level, which had persisted at > 10 mg/l for more than 2 weeks before admission, decreased from 13.8 mg/l to 6.6 mg/l and the ß-d-glucan became negative (< 3.57 pg/ml) following an increase in itraconazole from 100 mg to 200 mg during the 4 days until the diagnosis was made. In fact, the MIC of itraconazole was low and itraconazole had good in vitro activity against the fungus isolated. Although the MIC of itraconazole was very low (0.03 mg/l), the patient developed fungal osteomyelitis during itraconazole prophylaxis. In general, in vitro susceptibility testing for slowgrowing organisms are problematic and not standardized [18] . The MICs of the present isolate were established after 5 days of incubation, but true MIC endpoints may have needed a longer incubation time because the isolated fungus grew extremely slowly. Furthermore, antifungal pharmacodynamic parameters in RPMI-1640, which is the standard synthetic medium for in vitro antifungal susceptibility testing, may not always predict antifungal activity in serum for azoles. In particular, highly proteinbound antifungal agents, such as itraconazole (protein binding, 99.8%), have a trend toward higher MICs in the presence of serum [19] . In addition, the patient had taken prophylactic itraconazole capsules without food for several months before hospitalization. As a result, plasma concentrations of itraconazole may have decreased. Thus, we attribute the failure of the prophylaxis to decreasing plasma concentrations of itraconazole. Therapy with escalating concentrations of itraconazole resulted in improved laboratory test results. Plasma itraconazole concentrations should be measured when there is failure of prophylaxis or treatment. This is the first reported case of osteomyelitis due to dematiaceous fungi in CGD patients. The causative agent was found to be an extremely rare microorganism, C. arxii. The patient was successfully treated with surgical debridement, increasing concentrations of itraconazole, and IFN-c treatment.
